A Phase I Study of MGCD0103 Given Three-Times Weekly In Patients With Leukemia Or Myelodysplastic Syndromes

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

July 31, 2006

Study Completion Date

December 31, 2008

Conditions

LeukemiaMyelodysplastic Syndromes

Interventions

DRUG

MGCD0103

MGCD0103 given orally three times per week.

Trial Locations (3)

Anderson Cancer Center, Houston

Princess Margaret Hospital, Toronto

Sir Mortimer Davis-Jewish General Hospital, Montreal